NeOnc Technologies Announces FDA Rescheduled NEO212 End-of-Phase 1 Type B Meeting to November 23
Key Highlights
- ➤FDA meeting rescheduled to November 23, 2026, for NEO212 Phase 2 planning feedback
- ➤610 mg selected as NEO212’s recommended Phase 2 dose after 810 mg toxicity
- ➤NEO212 produced approximately 60% tumor reduction in one recurrent GBM patient
- ➤NEO212 delivered stable disease for approximately 16 months in metastatic brain cancer patient
Expert Statements
Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer of NeOnc
“We believe the durable activity NEO212 showed in Phase 1, together with a well-defined recommended Phase 2 dose, gives us a compelling foundation for the next stage of development.”
Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer of NeOnc
“We look forward to discussing our Phase 2 plans with the FDA as we work to advance NEO212 for patients with CNS cancers who urgently need new options.”
CALABASAS, Calif., Nov. 19, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced that the U.S. Food and Drug Administration (FDA) has rescheduled the Company’s End-of-Phase 1 Type B meeting concerning oral NEO212 from the previously announced date of November 17, 2026, to Monday, November 23, 2026.
At the meeting, NeOnc intends to seek FDA feedback on its NEO212 clinical development program, including the proposed patient population, trial design, endpoints and dose selection for the Phase 2 portions of the NEO212-01 trial, as well as potential regulatory pathways for NEO212. The meeting provides an opportunity for discussion; its scheduling does not establish FDA agreement on a trial design or eventual approval of NEO212.
Get started
Create a free account to read the full story.
